Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Portage Biotech Inc ( (PRTG) ) has provided an announcement.
On February 12, 2025, Portage Biotech Inc. announced that it received an extension from Nasdaq to comply with the stock exchange’s minimum shareholders’ equity requirement. This extension allows the company to continue its listing on the Nasdaq Capital Market while they work towards meeting these standards. Failure to comply by June 9, 2025, or not showing consistent progress could lead to delisting proceedings. This development is crucial for Portage Biotech as it strives to maintain its market position and provide confidence to its stakeholders.
More about Portage Biotech Inc
Portage Biotech Inc. is a clinical-stage immuno-oncology company that is developing a portfolio of innovative therapeutics aimed at enhancing the immune system’s ability to combat cancer.
YTD Price Performance: 3.28%
Average Trading Volume: 705,442
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.34M
See more data about PRTG stock on TipRanks’ Stock Analysis page.
